Susan Altschuller
Director of Finance/CFO bei CEREVEL THERAPEUTICS HOLDINGS, INC.
Vermögen: 714 913 $ am 31.03.2024
Profil
Dr. Susan Altschuller is an Independent Director at Mural Oncology Plc, a Chief Financial Officer at Cerevel Therapeutics Holdings, Inc., a Chief Financial Officer at Cerevel Therapeutics, Inc. and a Founding Member at HNRNP Family Foundation.
She is on the Board of Directors at Mural Oncology Plc and Vestaron Corp.
Dr. Altschuller was previously employed as a Chief Financial Officer & Senior Vice President by ImmunoGen, Inc., a Head-Enterprise Finance by Alexion Pharmaceuticals, Inc., a Head-Investor Relations by Biogen, Inc., and a Head-Investor Relations by Bioverativ, Inc. She received her undergraduate degree from Tulane University (Louisiana), an MBA from MIT Sloan School of Management and a doctorate degree from Illinois Institute of Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.01.2024 | 16 913 ( 0,01% ) | 714 913 $ | 31.03.2024 |
Aktive Positionen von Susan Altschuller
| Unternehmen | Position | Beginn |
|---|---|---|
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Director of Finance/CFO | 15.05.2023 |
Vestaron Corp.
 Vestaron Corp. Chemicals: SpecialtyProcess Industries Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC. | Director/Board Member | - |
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Director of Finance/CFO | 01.05.2023 |
Ehemalige bekannte Positionen von Susan Altschuller
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNOGEN, INC. | Director of Finance/CFO | 23.12.2022 |
| ALEXION PHARMACEUTICALS, INC. | Investor Relations Contact | 01.07.2020 |
| BIOVERATIV INC | Public Communications Contact | - |
| BIOGEN INC. | Investor Relations Contact | - |
Ausbildung von Susan Altschuller
| Illinois Institute of Technology | Doctorate Degree |
| Tulane University (Louisiana) | Undergraduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Vestaron Corp.
Vestaron Corp. Chemicals: SpecialtyProcess Industries Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC. | Process Industries |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Health Technology |
